CRONCronos Group Inc.

$983M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$30M+26.7% YoY

Gross Profit

$11M35.7% margin

Operating Income

-$11M-37.5% margin

Net Income

$44M144.3% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

-11.6%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$55M

Stockholders' Equity

$1.1B

Cash & Equivalents

$859M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$24M	+26.7%
Gross Profit	$11M	$2M	+464.9%
Operating Income	-$11M	-$22M	+47.5%
Net Income	$44M	-$45M	+197.6%

Revenue Segments

Cannabis Flower

$70M76%

Cannabis Extracts

$21M23%

Product and Service, Other

$499,0001%

CRON Q4 2024 Earnings — Cronos Group Inc. Revenue & Financial Results | Market Cap Arena